Literature DB >> 1245939

Clinical reactions and serologic response following inactivated monovalent influenza type B vaccine in young children and infants.

P F Wright, S H Sell, J Thompson, D T Karzon.   

Abstract

A monovalent, zonally purified, inactivated influenza B vaccine was administered to 29 children, 3 to 6 years of age, and 16 infants, 12 to 28 months of age, as a single dose of 0.25 ml containing 250 chick cell agglutinating units. The vaccine was both antigenic and well tolerated in the older group of preschool children. In the infants the vaccine was also antigenic but poorly tolerated clinically. Febrile reactions to 102 or greater were seen in 9 of the 16 infants, and two of these infants experienced a seizure following vaccination. The clinical reactions observed with the administration of influenza B vaccine in the dose used in this study would suggest significant limitations on its use in children under 3 years of age.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1245939     DOI: 10.1016/s0022-3476(76)80722-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  11 in total

1.  Host defence mechanisms against influenza infection. II. Protection of mice with vaccines against A/Port Chalmers/1/73 and B/Hong Kong/5/72.

Authors:  F A Ennis; M A Wells; D W Barry; S Daniel; J Manischewitz
Journal:  Postgrad Med J       Date:  1976-06       Impact factor: 2.401

2.  Reactogenicity and immunogenicity of a surface-antigen-adsorbed influenza virus vaccine in children.

Authors:  L M Eastwood; R Jennings; R D Milner; C W Potter
Journal:  J Clin Pathol       Date:  1979-06       Impact factor: 3.411

Review 3.  Vaccines for preventing influenza in healthy children.

Authors:  Tom Jefferson; Alessandro Rivetti; Carlo Di Pietrantonj; Vittorio Demicheli; Eliana Ferroni
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

4.  Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age.

Authors:  Natasha B Halasa; Michael A Gerber; Andrea A Berry; Edwin L Anderson; Patricia Winokur; Harry Keyserling; Allison Ross Eckard; Heather Hill; Mark C Wolff; Monica M McNeal; Kathryn M Edwards; David I Bernstein
Journal:  J Pediatric Infect Dis Soc       Date:  2014-06-27       Impact factor: 3.164

5.  [Vaccination of infants and schoolchildren with an influenza subunit vaccine (author's transl)].

Authors:  O Jürgenssen; A Moritz; E Liehl; H Bachmayer
Journal:  Infection       Date:  1978       Impact factor: 3.553

6.  Safety and immunogenicity of trivalent inactivated influenza vaccine in infants.

Authors:  Natasha B Halasa; Michael A Gerber; Qingxia Chen; Peter F Wright; Kathryn M Edwards
Journal:  J Infect Dis       Date:  2008-05-15       Impact factor: 5.226

7.  Antibody responses after inactivated influenza vaccine in young children.

Authors:  Peter F Wright; Edith Sannella; Jian R Shi; Yuwei Zhu; Mine R Ikizler; Kathryn M Edwards
Journal:  Pediatr Infect Dis J       Date:  2008-11       Impact factor: 2.129

8.  Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season.

Authors:  Lisa A Grohskopf; Leslie Z Sokolow; Karen R Broder; Emmanuel B Walter; Joseph S Bresee; Alicia M Fry; Daniel B Jernigan
Journal:  MMWR Recomm Rep       Date:  2017-08-25

Review 9.  Vaccines for preventing influenza in healthy children.

Authors:  Tom Jefferson; Alessandro Rivetti; Carlo Di Pietrantonj; Vittorio Demicheli
Journal:  Cochrane Database Syst Rev       Date:  2018-02-01

10.  Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season.

Authors:  Lisa A Grohskopf; Leslie Z Sokolow; Karen R Broder; Emmanuel B Walter; Alicia M Fry; Daniel B Jernigan
Journal:  MMWR Recomm Rep       Date:  2018-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.